SCHEDULE: FMR LLC, Abigail Johnson Disclose 6.3% Stake in Mineralys

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have disclosed a 6.3% beneficial ownership stake in Mineralys Therapeutics Inc. as of December 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson, its Chairman and CEO, collectively reported beneficial ownership of 5,017,509 shares of Mineralys Therapeutics Inc. common stock.
• This aggregate amount represents 6.3% of Mineralys Therapeutics Inc.'s total outstanding common stock.
• FMR LLC holds sole voting power over 5,013,931 shares and sole dispositive power over 5,017,509 shares.
• Abigail P. Johnson holds sole dispositive power over 5,017,509 shares.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Mineralys Therapeutics Inc.
• Several FMR LLC subsidiaries, including Fidelity Management & Research Company LLC, FIAM LLC, Fidelity Institutional Asset Management Trust Company, and Strategic Advisers LLC, are identified as entities beneficially owning shares, with Fidelity Management & Research Company LLC owning 5% or greater.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by a major institutional investor like FMR LLC can signal confidence in the company's long-term prospects and potentially attract further investment.

Positives

• A significant 6.3% stake by a major institutional investor like FMR LLC (Fidelity) can signal confidence in Mineralys Therapeutics Inc.'s long-term prospects.
• The investment is stated to be in the ordinary course of business, suggesting a strategic portfolio allocation rather than an activist position.

Risks

• The filing itself does not detail specific risks related to Mineralys Therapeutics Inc.'s operations or financial health, as it is a disclosure of beneficial ownership.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Mineralys Therapeutics Inc.'s future performance or strategic direction.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that a significant stake by a prominent asset manager like FMR LLC (Fidelity) in a therapeutics company often indicates a belief in the company's long-term growth potential, particularly in the often volatile biotechnology and pharmaceutical sectors. Such an investment can lend credibility and attract further institutional interest, potentially stabilizing the stock or providing a floor during market fluctuations.

Comparison to Industry Standards

• StockSavvy.ai observes that a 6.3% stake is a substantial position for an institutional investor, placing FMR LLC among the top shareholders of Mineralys Therapeutics Inc. While specific comparable companies or projects are not detailed in this filing, such a significant holding by a major fund like Fidelity is generally viewed positively, aligning with typical institutional investment strategies in emerging or specialized sectors where long-term growth is anticipated. For instance, similar significant stakes are often seen in early-stage biotech firms by large funds, such as BlackRock's or Vanguard's holdings in companies like Moderna or BioNTech during their growth phases, signaling confidence in future product pipelines or market penetration.

Related Party Transactions

• The filing discloses that Abigail P. Johnson is a Director, Chairman, and Chief Executive Officer of FMR LLC, and a predominant owner of FMR LLC's voting shares, establishing a related party relationship between the reporting persons. However, no specific related party transactions between Mineralys Therapeutics Inc. and FMR LLC or Abigail P. Johnson, beyond the beneficial ownership of shares, are detailed.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by FMR LLC may increase investor confidence and potentially lead to positive market sentiment for Mineralys Therapeutics Inc.
• Company Management: A large institutional investor may engage with management on strategic matters, though the filing states the investment is not for influencing control.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to monitor their beneficial ownership in Mineralys Therapeutics Inc.
• Future Schedule 13G/A filings will be made if there are material changes to their ownership percentage or intent.

Key Dates

Recommendation

While the disclosure of a significant stake by a reputable institutional investor like FMR LLC is generally a positive signal, this filing primarily provides ownership information rather than new operational or financial performance data for Mineralys Therapeutics Inc. A 'hold' recommendation is appropriate as it acknowledges the positive signal of institutional confidence without suggesting immediate action based solely on this ownership disclosure, pending further fundamental analysis of Mineralys Therapeutics Inc.'s business and financial health.

Keywords

Mineralys Therapeutics Inc, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Fidelity, Biotechnology, Pharmaceuticals